Endo International PLC (NASDAQ:ENDP) (TSE:ENL) shares fell 5.9% during mid-day trading on Thursday . The stock traded as low as $3.88 and last traded at $3.96, 5,859,716 shares changed hands during trading. An increase of 57% from the average session volume of 3,737,711 shares. The stock had previously closed at $4.21.

Several brokerages have recently issued reports on ENDP. Citigroup cut their price target on Thor Industries from $78.00 to $70.00 in a research note on Monday, June 17th. JPMorgan Chase & Co. upped their price target on Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Gabelli reissued a “hold” rating on shares of Endo International in a research note on Wednesday, March 27th. SunTrust Banks began coverage on Zoetis in a research note on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Finally, Zacks Investment Research lowered HEXO from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $11.57.

The firm has a market capitalization of $895.68 million, a P/E ratio of 1.37 and a beta of 1.16. The firm has a 50-day moving average price of $4.60.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.11. The company had revenue of $720.00 million for the quarter, compared to analyst estimates of $692.31 million. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. Endo International’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 earnings per share. On average, equities research analysts forecast that Endo International PLC will post 2.17 EPS for the current year.

In other news, Director Roger H. Kimmel sold 34,951 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the sale, the director now owns 148,309 shares of the company’s stock, valued at $582,854.37. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its position in shares of Endo International by 37.5% in the 1st quarter. Nordea Investment Management AB now owns 177,700 shares of the company’s stock valued at $1,427,000 after buying an additional 48,500 shares during the last quarter. Factorial Partners LLC bought a new stake in shares of Endo International in the 1st quarter valued at about $193,000. Acadian Asset Management LLC grew its position in shares of Endo International by 83,573.5% in the 1st quarter. Acadian Asset Management LLC now owns 771,470 shares of the company’s stock valued at $6,194,000 after buying an additional 770,548 shares during the last quarter. Piedmont Investment Advisors Inc. grew its position in shares of Endo International by 5.8% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock valued at $407,000 after buying an additional 2,795 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Endo International by 24.8% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,900,414 shares of the company’s stock valued at $15,260,000 after buying an additional 378,182 shares during the last quarter. 93.59% of the stock is currently owned by institutional investors.

About Endo International (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Article: Bond

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.